Home Cart 0 Sign in  

[ CAS No. 1300031-49-5 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
Chemical Structure| 1300031-49-5
Chemical Structure| 1300031-49-5
Structure of 1300031-49-5 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 1300031-49-5 ]

Related Doc. of [ 1300031-49-5 ]

Alternatived Products of [ 1300031-49-5 ]

Product Details of [ 1300031-49-5 ]

CAS No. :1300031-49-5 MDL No. :MFCD22124472
Formula : C23H21N5O3 Boiling Point : -
Linear Structure Formula :- InChI Key :VUVUVNZRUGEAHB-CYBMUJFWSA-N
M.W : 415.44 Pubchem ID :52912189
Synonyms :
GSK1210151A
Chemical Name :7-(3,5-Dimethylisoxazol-4-yl)-8-methoxy-1-((R)-1-(pyridin-2-yl)ethyl)-1H-imidazo[4,5-c]quinolin-2(3H)-one

Calculated chemistry of [ 1300031-49-5 ]      Expand+

Physicochemical Properties

Num. heavy atoms : 31
Num. arom. heavy atoms : 24
Fraction Csp3 : 0.22
Num. rotatable bonds : 4
Num. H-bond acceptors : 6.0
Num. H-bond donors : 1.0
Molar Refractivity : 118.13
TPSA : 98.83 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : No
P-gp substrate : Yes
CYP1A2 inhibitor : No
CYP2C19 inhibitor : No
CYP2C9 inhibitor : Yes
CYP2D6 inhibitor : No
CYP3A4 inhibitor : Yes
Log Kp (skin permeation) : -6.9 cm/s

Lipophilicity

Log Po/w (iLOGP) : 2.91
Log Po/w (XLOGP3) : 2.72
Log Po/w (WLOGP) : 4.16
Log Po/w (MLOGP) : 1.68
Log Po/w (SILICOS-IT) : 4.51
Consensus Log Po/w : 3.2

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 0.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -4.44
Solubility : 0.0151 mg/ml ; 0.0000365 mol/l
Class : Moderately soluble
Log S (Ali) : -4.45
Solubility : 0.0148 mg/ml ; 0.0000355 mol/l
Class : Moderately soluble
Log S (SILICOS-IT) : -8.04
Solubility : 0.00000375 mg/ml ; 0.000000009 mol/l
Class : Poorly soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 0.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 3.94

Safety of [ 1300031-49-5 ]

Signal Word:Danger Class:6.1
Precautionary Statements:P264-P270-P301+P310-P321-P330-P405-P501 UN#:2811
Hazard Statements:H301 Packing Group:
GHS Pictogram:

Application In Synthesis of [ 1300031-49-5 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 1300031-49-5 ]
  • Downstream synthetic route of [ 1300031-49-5 ]

[ 1300031-49-5 ] Synthesis Path-Upstream   1~15

  • 1
  • [ 1300737-69-2 ]
  • [ 1300031-49-5 ]
YieldReaction ConditionsOperation in experiment
77% With [bis(acetoxy)iodo]benzene; potassium hydroxide In methanol for 1.33333 h; Cooling with ice 7-(3,5-Dimethyl-4-isoxazolyl)-6-(methyloxy)-4-[(1R)-1-(2-pyridinyl)ethyl]amino}-3-quinolinecarboxamide (45 g, 102 mmol) was dissolved in methanol (500 mL) and potassium hydroxide (7.47 g, 133 mmol) was added. The mixture was stirred in an ice bath, then iodobenzene diacetate (39.6 g, 123 mmol) was added in small portions over 20 min and the mixture stirred for a further 1 h. The solvent was evaporated in vacuo, the residue diluted with water (1 L), and the resulting gummy suspension extracted with DCM (2 x 300 mL). The solvent was dried (sodium sulphate) and loaded directly onto a silica column (750 g), which was then eluted with a 2M ammonia in methanol / DCM gradient (0-10percent). After evaporation of solvents in vacuo 7-(3,5-dimethyl-4-isoxazolyl)-8-(methyloxy)-1-[(1R)-1-(2-pyridinyl)ethyl]-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one (32.7 g, 77percent yield) was obtained as a beige solid. 1H-NMR (600 MHz, DMSO-d6) d ppm 2.03 (d, J=6.5 Hz, 3 H), 2.04 (s, 3 H), 2.25 (s, 3 H), 3.46 (bs, 3 H), 6.26 (q, J=7.1 Hz, 1 H), 6.69 (bs, 1 H), 7.35 (dd, J=7.0, 5.1 Hz, 1 H), 7.41 (d, J=6.6 Hz, 1 H), 7.76-7.79 (m, 1 H), 7.79 (s, 1 H), 8.59-8.65 (m, 2 H), 11.77 (bs, 1H). 13C NMR (151 MHz, DMSO-d6) d ppm 10.3, 11.3, 17.6, 51.8, 55.5, 100.8, 112.0, 115.4, 120.2, 121.0, 122.7, 122.7, 128.1, 132.3, 132. 8, 137.6, 139.8, 149.3, 154.3, 154.5, 159.0, 159.2, 166.0. MS (Method HpH): MH+ 416, Rt 0.85 min. HRMS (m/z): [MH]+ calcd for C23H22N5O3 416.1723; found 416.1718.
33% With [bis-(trifluoroacetoxy)iodo]benzene In acetonitrile at 20℃; The carboxamide intermediate (6 g) was treated with an excess of [bis(trifluoroacetoxy)iodo]benzene (19.35 g, 45 mmol) in CH3CN (100 ml), the mixture was stirred at room temperature overnignt.
The reaction mixture was concentrated in vacuo, the resulting residue was dissolved in DCM and washed with water.
The crude product was purified by flash chromatography on silica gel (DCM/MeOH, 95:5), the resulting compound was dissolved in DCM and precipitated from diethylether to give the title compound as an off-white powder (2.5 g, 33percent)
LC-HRMS ES+ exact mass calculated for C23H21N5O3: 416.1722 MH+.
Found 416.1736, Rt=2.22 min. (APCI-MS) m/z 415.97 MH+, Rt 2.5 min.
Reference: [1] Bioorganic and Medicinal Chemistry Letters, 2012, vol. 22, # 8, p. 2963 - 2967
[2] Patent: US2012/232074, 2012, A1, . Location in patent: Page/Page column 33
[3] Patent: WO2011/54846, 2011, A1, . Location in patent: Page/Page column 84
  • 2
  • [ 16114-47-9 ]
  • [ 1300031-49-5 ]
Reference: [1] Bioorganic and Medicinal Chemistry Letters, 2012, vol. 22, # 8, p. 2963 - 2967
[2] Patent: US2012/232074, 2012, A1,
[3] Patent: WO2011/54846, 2011, A1,
  • 3
  • [ 5399-03-1 ]
  • [ 1300031-49-5 ]
Reference: [1] Bioorganic and Medicinal Chemistry Letters, 2012, vol. 22, # 8, p. 2963 - 2967
[2] Patent: US2012/232074, 2012, A1,
[3] Patent: WO2011/54846, 2011, A1,
  • 4
  • [ 1300031-62-2 ]
  • [ 1300031-49-5 ]
Reference: [1] Bioorganic and Medicinal Chemistry Letters, 2012, vol. 22, # 8, p. 2963 - 2967
[2] Patent: US2012/232074, 2012, A1,
[3] Patent: WO2011/54846, 2011, A1,
  • 5
  • [ 1300031-61-1 ]
  • [ 1300031-49-5 ]
Reference: [1] Bioorganic and Medicinal Chemistry Letters, 2012, vol. 22, # 8, p. 2963 - 2967
[2] Patent: US2012/232074, 2012, A1,
[3] Patent: WO2011/54846, 2011, A1,
  • 6
  • [ 1300031-60-0 ]
  • [ 1300031-49-5 ]
Reference: [1] Bioorganic and Medicinal Chemistry Letters, 2012, vol. 22, # 8, p. 2963 - 2967
[2] Patent: US2012/232074, 2012, A1,
[3] Patent: WO2011/54846, 2011, A1,
  • 7
  • [ 1300031-58-6 ]
  • [ 1300031-49-5 ]
Reference: [1] Patent: US2012/232074, 2012, A1,
[2] Patent: WO2011/54846, 2011, A1,
  • 8
  • [ 1300735-40-3 ]
  • [ 1300031-49-5 ]
  • [ 1300735-41-4 ]
Reference: [1] Patent: WO2011/54846, 2011, A1, . Location in patent: Page/Page column 86
[2] Patent: US2012/232074, 2012, A1, . Location in patent: Page/Page column 39
  • 9
  • [ 1300031-59-7 ]
  • [ 1300031-49-5 ]
Reference: [1] Patent: WO2011/54846, 2011, A1,
  • 10
  • [ 1300031-57-5 ]
  • [ 1300031-49-5 ]
Reference: [1] Patent: US2012/232074, 2012, A1,
[2] Patent: WO2011/54846, 2011, A1,
  • 11
  • [ 1300031-59-7 ]
  • [ 1300031-49-5 ]
Reference: [1] Bioorganic and Medicinal Chemistry Letters, 2012, vol. 22, # 8, p. 2963 - 2967
[2] Patent: US2012/232074, 2012, A1,
  • 12
  • [ 1300031-58-6 ]
  • [ 1300031-49-5 ]
Reference: [1] Bioorganic and Medicinal Chemistry Letters, 2012, vol. 22, # 8, p. 2963 - 2967
[2] Patent: US2012/232074, 2012, A1,
  • 13
  • [ 1300737-83-0 ]
  • [ 1300031-49-5 ]
  • [ 1300735-41-4 ]
Reference: [1] Patent: US2012/232074, 2012, A1,
[2] Patent: WO2011/54846, 2011, A1,
  • 14
  • [ 27854-90-6 ]
  • [ 1300031-49-5 ]
Reference: [1] Patent: WO2011/54846, 2011, A1,
  • 15
  • [ 1300031-57-5 ]
  • [ 27854-90-6 ]
  • [ 1300031-49-5 ]
Reference: [1] Bioorganic and Medicinal Chemistry Letters, 2012, vol. 22, # 8, p. 2963 - 2967
Recommend Products
Same Skeleton Products
Historical Records